Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma

Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma

Abstract Background and Aim Standardization of the sedation protocol during radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC) is needed. This randomized, single‐blind, investigator‐initiated trial compared clinical outcomes during and after RFA using propofol and midazola...

Full description

Bibliographic Details
Main Authors: Naoya Kanogawa, Sadahisa Ogasawara, Yoshihiko Ooka, Masanori Inoue, Toru Wakamatsu, Masayuki Yokoyama, Susumu Maruta, Hidemi Unozawa, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Keisuke Koroki, Hiroaki Kanzaki, Takahiro Maeda, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Tenyu Motoyama, Eiichiro Suzuki, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Jun Kato, Ryo Takemura, Natsuko Nozaki‐Taguchi, Isono Shiroh, Osamu Yokosuka, Naoya Kato
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:JGH Open
Subjects:
hepatocellular carcinoma
midazolam
propofol
radiofrequency ablation
sedation
Online Access:https://doi.org/10.1002/jgh3.12483

Internet

https://doi.org/10.1002/jgh3.12483

Similar Items